Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2017 08:00 ET | Source: Editas Medicine

Editas Medicine to Participate in Investor Conferences in June

CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
May 31, 2017 16:01 ET | Source: Editas Medicine

Editas Medicine Names Andrew Hirsch to Board of Directors

CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors,...
May 15, 2017 16:01 ET | Source: Editas Medicine

Editas Medicine Announces First Quarter 2017 Results and Update

Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on...
May 13, 2017 11:05 ET | Source: Editas Medicine

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas

CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first...
May 11, 2017 09:15 ET | Source: Editas Medicine

Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC)...
May 08, 2017 16:01 ET | Source: Editas Medicine

Editas Medicine to Present at Investor Conferences in May

CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
May 08, 2017 16:01 ET | Source: Editas Medicine

Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results

CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
April 24, 2017 14:17 ET | Source: Editas Medicine

Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting

Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell...
March 16, 2017 21:04 ET | Source: Editas Medicine

Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000...
March 15, 2017 16:14 ET | Source: Editas Medicine

Editas Medicine, Inc., Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of...